Title |
The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters
|
---|---|
Published in |
BMC Cancer, August 2009
|
DOI | 10.1186/1471-2407-9-290 |
Pubmed ID | |
Authors |
W Al Sarakbi, W Sasi, WG Jiang, T Roberts, RF Newbold, K Mokbel |
Abstract |
SET domain containing protein 2 (SETD2) is a histone methyltransferase that is involved in transcriptional elongation. There is evidence that SETD2 interacts with p53 and selectively regulates its downstream genes. Therefore, it could be implicated in the process of carcinogenesis. Furthermore, this gene is located on the short arm of chromosome 3p and we previously demonstrated that the 3p21.31 region of chromosome 3 was associated with permanent growth arrest of breast cancer cells. This region includes closely related genes namely: MYL3, CCDC12, KIF9, KLHL18 and SETD2. Based on the biological function of these genes, SETD2 is the most likely gene to play a tumour suppressor role and explain our previous findings. Our objective was to determine, using quantitative PCR, whether the mRNA expression levels of SETD2 were consistent with a tumour suppressive function in breast cancer. This is the first study in the literature to examine the direct relationship between SETD2 and breast cancer. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 1% |
Unknown | 70 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 21 | 30% |
Researcher | 13 | 18% |
Student > Master | 10 | 14% |
Student > Bachelor | 7 | 10% |
Student > Doctoral Student | 3 | 4% |
Other | 10 | 14% |
Unknown | 7 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 28 | 39% |
Biochemistry, Genetics and Molecular Biology | 20 | 28% |
Medicine and Dentistry | 9 | 13% |
Immunology and Microbiology | 1 | 1% |
Neuroscience | 1 | 1% |
Other | 0 | 0% |
Unknown | 12 | 17% |